Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on concomitant treatment with GLP-1 therapy – – Analysis of data ...

If claiming for a Documented Loss Cash Payment for the AT&T 1 Data Incident and a Documented Loss Cash Payment for the AT&T 2 ...

Abstract available on ASH websiteSAN DIEGO and TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” ...

This study investigates the folding and unfolding behavior of the doubly knotted protein TrmD-Tm1570, providing insight into the molecular mechanisms underlying protein knotting. The findings reveal ...

Novel combination with neoadjuvant eftilagimod alfa (efti) achieves significant 51.5% tumour hyalinization/fibrosis across ...

ADVANCED-2 (NCT05951179) is a Phase 2 open-label trial assessing intravesical TARA-002 in NMIBC patients with carcinoma in situ or CIS (± Ta/T1) who are Bacillus Calmette-Guérin (BCG)-Unresponsive ...

RELATED: 3 Small Habits Of Exceptionally Calm People Who Rarely Get Rattled, According To Psychology Habits or patterns of ...

Analysis based on claims data highlights significant cost savings, especially among high-risk members NEW YORK, Nov. 12, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", ...

Cannae Holdings, Inc. (NYSE: CNNE) ("Cannae" or the "Company") today announced that it has released an investor presentation in connection with its 2025 Annual Meeting of Shareholders (the "Annual ...

Branvas reports a shift in dropshipping from generic hustles to brand-driven businesses, emphasizing trust, customer ...

New criteria that put greater emphasis on body composition to diagnose obesity show greater prevalence of the disease in the ...